贝鲁莫司地尔治疗弥漫性皮肤型系统性硬化症:一项随机、双盲、开放标签扩展、安慰剂对照的2期研究
该2期研究将弥漫性皮肤型系统性硬化症患者按1:1:1随机分配至贝鲁莫司地尔200mg每日一次、每日两次或安慰剂组治疗28周,双盲期后进入24周开放标签扩展。主要终点第24周CRISS评分≥0.60在贝鲁莫司地尔组与安慰剂组间未见疗效信号,药物耐受性良好,组织RNA测序显示CRISS≥0.60患者FOXP3上调及STAT3、IL23A、TGF-β下调,贝鲁莫司地尔组纤维化生物标志物呈下降趋势。
要点
- 主要终点第24周CRISS评分≥0.60未显示疗效信号:每日一次组OR 1.06(0.19-5.82;P=0.9472),每日两次组OR 0.39(0.07-2.35;P=0.3078)。
- 贝鲁莫司地尔耐受性良好,双盲期与开放标签期安全性特征相似。
- CRISS评分≥0.60患者组织RNA测序显示FOXP3上调及STAT3、IL23A、TGF-β下调,支持贝鲁莫司地尔作用机制。
核心结论
- 未能检测到贝鲁莫司地尔的疗效信号。
- 信号通路调节分析支持贝鲁莫司地尔的作用机制。
- 贝鲁莫司地尔治疗组观察到纤维化相关生物标志物下降趋势。
研究设计与样本
- 随机、双盲、开放标签扩展、安慰剂对照的2期研究。
- eligible患者按1:1:1随机分配至贝鲁莫司地尔200mg每日一次、每日两次或安慰剂组治疗28周(双盲期)。
- 揭盲后,接受贝鲁莫司地尔者继续相同剂量,接受安慰剂者重新随机分配至一种贝鲁莫司地尔剂量治疗24周(开放标签扩展)。
- 双盲期和开放标签期分别有35例和31例患者接受治疗。
- 研究提前终止,未达到目标入组人数。
主要发现
- 主要终点第24周CRISS评分≥0.60在贝鲁莫司地尔组与安慰剂组间未显示疗效信号:每日一次组OR 1.06(0.19-5.82;P=0.9472),每日两次组OR 0.39(0.07-2.35;P=0.3078)。
- 贝鲁莫司地尔耐受性良好,双盲期与开放标签期安全性特征相似。
- 组织RNA测序分析显示,CRISS评分≥0.60患者FOXP3上调及STAT3、IL23A和TGF-β下调,支持贝鲁莫司地尔的作用机制。
- 在血液和组织样本中,贝鲁莫司地尔治疗组与安慰剂组相比观察到纤维化生物标志物水平下降趋势。
局限性
- 研究提前终止,未达到目标入组人数。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the efficacy, safety and pharmacodynamics of belumosudil in patients with diffuse cutaneous systemic sclerosis (dcSSc) treated with background immunosuppressive therapies. METHODS: Eligible patients were randomised 1:1:1 to receive belumosudil 200 mg once daily (QD) or twice daily (BID), or placebo for 28 weeks (double-blind period). After unblinding, the patients who received belumosudil continued the same dose, whereas the patients who received placebo were re-randomised for one of the belumosudil doses for 24 weeks (open-label extension). RESULTS: Thirty-five and 31 patients were treated in the double-blind and open-label periods, respectively. The study was terminated prematurely, and target enrolment was not met. The primary end point, of CRISS score ≥0.60 at week 24, did not exhibit an efficacy signal in the belumosudil vs placebo groups [odds ratio: 1.06 (0.19-5.82; P = 0.9472) for the QD, and 0.39 (0.07-2.35; P = 0.3078) for the BID group]. Belumosudil was well tolerated and exhibited similar safety profiles in both double-blind and open-label periods. Tissue-based RNA sequencing analysis revealed FOXP3 upregulation and STAT3, IL23A and TGF-β downregulation in patients with CRISS score ≥0.60, which supported the mechanism of action of belumosudil. In blood and tissue samples, trends of decreased fibrosis biomarker levels were seen in the belumosudil-treated group vs placebo. CONCLUSION: Efficacy signal for belumosudil could not be detected. Signalling pathway modulation analysis supported the mechanism of action of belumosudil. A trend for decreased fibrosis-related biomarkers was observed in the belumosudil-treated group. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT03919799.
引用
- Chung L, Silver RM, Steen V, et al. Belumosudil in diffuse cutaneous systemic sclerosis: a randomized, double-blind, open-label extension, placebo-controlled, phase 2 study. Rheumatology (Oxford). 2025. PMID: 40088930. doi:10.1093/rheumatology/keaf062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。